Biogen prices new MS drug at discount to key competitors

Your Health Matters

A pedestrian passes the sign outside the headquarters of Biogen Idec Inc. in CambridgeWASHINGTON (Reuters) – Biogen Idec Inc said on Friday it will charge $54,900 a year for its multiple sclerosis drug, Tecfidera, which received U.S. approval on Wednesday. The company has priced the drug at a discount to key competitors such as Novartis AG's MS pill Gilenya, which costs roughly $60,000 a year, in a bid to maximize its market share. "We think this represents solid value to the MS community and demonstrates our commitment to patient access," said Kate Niazi-Sai, a Biogen spokeswoman. …

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave